Guest guest Posted December 3, 2010 Report Share Posted December 3, 2010 Blank B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. M Binder, F Muller, A Jackst, B Lechenne, M Pantic, U Bacher, CZ Eulenburg, H Veelken, R Mertelsmann, R Pasqualini, W Arap, and M Trepel Cancer, November 29, 2010; . Department of Oncology and Hematology, Hubertus Wald Cancer Center, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany. BACKGROUND:: B-cell receptors (BCRs) and their recognition of specific epitopes may play a pivotal role in the development and progression of chronic lymphocytic leukemia (CLL). In this study, the authors set up a model system to explore epitope reactivity and its clinical relevance in CLL. METHODS:: Epitope-mimicking peptides were selected from phage display libraries on 6 CLL BCRs from randomly chosen patients. The binding of the 6 index epitope mimics was evaluated in a set of 100 unrelated CLL samples. Epitope recognition patterns were correlated with the clinical course of the disease. RESULTS:: Surprisingly, all CLL samples recognized 1 or several index epitopes, and some revealed marked polyreactivity. Patients with CLL who expressed BCRs that reacted with ?5 epitope mimics had a significantly worse clinical course than less polyreactive patients (median time to first treatment, 24 months vs 102 months). This effect was independent of otherwise known prognostic markers. CONCLUSIONS:: The authors introduced a system with which to model epitope reactivity of CLL BCRs without previous knowledge of potential antigens. The findings indicated that a polyreactive epitope recognition pattern may be a determinant of an aggressive clinical course in this disease. This further emphasizes the functional and prognostic relevance of BCR epitope recognition in CLL. Cancer 2010. ? 2010 American Cancer Society. PMID: 21117166 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.